Using advanced microfluidic technology, zirconium and 5,10,15,20‐tetra(4‐pyridyl)porphyrin nanoparticles loaded with FOXK2 siRNA, enveloped in cell membrane, co‐encapsulated with metformin in gelatin methacrylate microspheres (ZrTCP@siFOXK2@CM/Met@GelMA) hydrogel microspheres, are introduced, highlighting a transformative strategy to target cancer's metabolic vulnerabilities effectively. The gene discussed is FOXK2; the disease is cancer.